{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:38:37Z","timestamp":1776533917332,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11906-005-0008-1","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T06:03:23Z","timestamp":1180073003000},"page":"186-192","source":"Crossref","is-referenced-by-count":10,"title":["Aldosterone antagonism: An emerging strategy for effective blood pressure lowering"],"prefix":"10.1007","volume":"7","author":[{"given":"Monique N.","family":"Pratt-Ubunama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari K.","family":"Nishizaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW: Presidential address. Part I: painting background; Part II: primary aldosteronism\u2014a new clinical syndrome. J Lab Clin Med 1955, 45:3\u201317.","journal-title":"J Lab Clin Med"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"RD Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315\u2013318.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonzalez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161\u2013165. This prospective study included a large number of normotensive and hypertensive subjects with different levels of blood pressure. It demonstrates an increasing prevalence of primary aldosteronism with increasing severity of hypertension.","journal-title":"Hypertension"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","volume":"12","author":"Po Lim","year":"2000","unstructured":"Lim Po, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 12:311\u2013314.","journal-title":"J Hum Hypertens"},{"key":"8_CR5","first-page":"1863","volume":"85","author":"CE Fardella","year":"2000","unstructured":"Fardella CE, Mosso L, Gomez-Sanchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863\u20131867.","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR6","first-page":"17","volume":"45","author":"A Kreeze","year":"1999","unstructured":"Kreeze A, Okalova D, Vanuga P, et al.: Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vintr Lek 1999, 45:17\u201321.","journal-title":"Vintr Lek"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896. This study provides the strong evidence that hyperaldosteronism is a common cause of resistant hypertension in both black and white subjects.","journal-title":"Hypertension"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"BJ Galley","year":"2001","unstructured":"Galley BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"8_CR9","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"IK Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin-status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217\u20132226.","journal-title":"J Hypertens"},{"key":"8_CR10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jama.1965.03090030022005","volume":"193","author":"JW Conn","year":"1965","unstructured":"Conn JW, Cohen EL, Rovner DR, et al.: Normokalemic primary aldosteronism: a detectable cause of curable \"essential\" hypertension. JAMA 1965, 193:200\u2013206.","journal-title":"JAMA"},{"key":"8_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33\u201341.","journal-title":"N Engl J Med"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930. This study demonstrates benefit of low-dose spironolactone as addon therapy in patients with resistant hypertension. The antihypertensive benefit occurred in the setting of ongoing diuretic and ACE inhibitor\/ARB use. Benefit was similar in subjects with and without primary aldosteronism, regardless of race.","journal-title":"Am J Hypertens"},{"key":"8_CR13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, et al.: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Carr AA, Krausse S, et al.: Assessment of novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003, 92:38\u201342.","journal-title":"Am J Cardiol"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"B White","year":"2003","unstructured":"White B, Duprez D, St Hillaire R, et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021\u20131026.","journal-title":"Hypertension"},{"key":"8_CR16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155.","journal-title":"J Am Coll Cardiol"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123.","journal-title":"Hypertension"},{"key":"8_CR18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333\u2013339.","journal-title":"Am J Hypertens"},{"key":"8_CR19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","volume":"48","author":"PO Lim","year":"1999","unstructured":"Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756\u2013760.","journal-title":"Br J Clin Pharmacol"},{"key":"8_CR20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","volume":"110","author":"H Schepkens","year":"2001","unstructured":"Schepkens H, Vanholder R, Billiouw J, et al.: Life-threatening hyperkalemia during combined therapy with angiotensinconverting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001, 110:438\u2013441.","journal-title":"Am J Med"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-131-2-199907200-00005","volume":"131","author":"RP Ghose","year":"1999","unstructured":"Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med 1999, 131:105\u2013108.","journal-title":"Ann Intern Med"},{"key":"8_CR22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00004872-200405000-00001","volume":"22","author":"NM Kaplan","year":"2004","unstructured":"Kaplan NM: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:863\u2013869.","journal-title":"J Hypertens"},{"key":"8_CR23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/00004872-200410000-00030","volume":"22","author":"JD Spence","year":"2004","unstructured":"Spence JD: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:2038\u20132039.","journal-title":"J Hypertens"},{"key":"8_CR24","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00004872-200410000-00032","volume":"22","author":"PH Krishnan","year":"2004","unstructured":"Krishnan PH, MacDonald T: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:2039\u20132040.","journal-title":"J Hypertens"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","volume":"60","author":"TL Goodfriend","year":"1999","unstructured":"Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401\u2013405.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"8_CR26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","volume":"125","author":"DA Calhoun","year":"2004","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112\u2013117.","journal-title":"Chest"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0008-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-005-0008-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0008-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:10Z","timestamp":1559434570000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-005-0008-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11906-005-0008-1","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}